Need Help?
Copied to clipboard!

HRDetect in Tubo-Ovarian Carcinoma: Stratification and Therapeutic Implications

HRDetect, a mutational-signature-based algorithm, was evaluated for prognostic utility and genomic classification in tubo-ovarian carcinoma (OC). Whole-genome sequencing (WGS) was performed on matched tumor-normal sample pairs from 185 patients with advanced-stage OC prospectively enrolled in a biorepository at University of Washington (UW cohort) and 77 patients from a clinical trial of the PARP inhibitor (PARPi) rucaparib in platinum-sensitive OC (ARIEL2 cohort). HRDetect scores were calculated using substitution signatures, rearrangement signatures (RS), microhomology-mediated deletions, and global loss of heterozygosity. In the UW cohort, cases scoring high on HRDetect had significantly longer median overall survival than others (6.2 vs 4.1 years; HR=0.6; 95% CI=0.41-0.87; p=0.007). 48.4% of HRDetect-high tumors had BRCA1/2 mutations or BRCA1 promoter hypermethylation, while 22.1% lacked alterations in BRCA1/2. Alterations were also detected in other key HRD genes, including RAD51C (mutation and promoter hypermethylation), RAD51D, PALB2, and BRIP1. Rearrangement signature profiling of HRDetect-intermediate cases (23.2% of UW cohort) identified eleven genomic clusters, with RS profiles RS1, RS14, and RS18 correlating with poor survival. In the ARIEL2 validation cohort, HRDetect-high tumors displayed better PARPi response rates (54% vs 22.5%) and progression-free survival (11.1 vs 7.1 months; HR=0.44; 95% CI=0.26-0.74; p=0.03) compared to non-HRDetect-high cases.

FASTQ files from WGS experiments are available for cases whose consents did not preclude genomic data sharing, including 51 from the UW cohort and 77 from the ARIEL2 cohort.